Ö. DİKMETAŞ Et Al. , "Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration," NORTHERN CLINICS OF ISTANBUL , vol.9, no.2, pp.173-179, 2022
DİKMETAŞ, Ö. Et Al. 2022. Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration. NORTHERN CLINICS OF ISTANBUL , vol.9, no.2 , 173-179.
DİKMETAŞ, Ö., Kadayifcila, S., Eldem, B., & Feyzullayeva, U., (2022). Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration. NORTHERN CLINICS OF ISTANBUL , vol.9, no.2, 173-179.
DİKMETAŞ, ÖZLEM Et Al. "Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration," NORTHERN CLINICS OF ISTANBUL , vol.9, no.2, 173-179, 2022
DİKMETAŞ, ÖZLEM Et Al. "Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration." NORTHERN CLINICS OF ISTANBUL , vol.9, no.2, pp.173-179, 2022
DİKMETAŞ, Ö. Et Al. (2022) . "Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration." NORTHERN CLINICS OF ISTANBUL , vol.9, no.2, pp.173-179.
@article{article, author={ÖZLEM DİKMETAŞ Et Al. }, title={Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration}, journal={NORTHERN CLINICS OF ISTANBUL}, year=2022, pages={173-179} }